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The majority of allergic diseases, including asthma, atopic derma-
titis and food allergy, are caused by allergen-specific IgE produc-
tion and Th2-polarized immune responses. Allergic sensitization 
is caused by DC activation of naïve T cells to generate and expand 
Th2-biased cellular immune responses, resulting in the produc-
tion of cytokines such as IL-4, IL-5 and IL-13. Th2 cytokines in-
duce the generation and expansion of allergen-specific IgE by B 
cells as well as accumulation of mast cells in tissues (Figure 1). 
Because of the central role Th2 immune responses play in the 
genesis of allergic disease, it is important to focus on therapeutic 
approaches capable of suppressing or redirecting these Th2 im-
mune responses.
The patent described herein (PCT/US2015/054943) covers the 
use of nanoemulsion compositions for the stimulation of immune re-
sponses capable of suppressing Th2-polarized immunity and reduc-
ing allergic disease.1 Nanoemulsions (NE) are nanoscale oil-in-water 
emulsions composed of a combination of surfactants, oil, ethanol 
and water. Our group has developed NE adjuvant formulations con-
sisting of soybean oil and a combination of cationic and nonionic sur-
factants with an average droplet size of 400-500 nm (Figure 1A).2 
These formulations provide adjuvant activity by enhancing the de-
livery of antigens as well as activating innate immune responses to 
boost immunity. We have previously reported that NE adjuvants can 
be formulated with a wide variety of antigen types and induce po-
tent Th1- and Th17-polarized mucosal, humoral and cellular immune 
responses after intranasal administration in both animal models and 
humans.3,4
The NE-based vaccine adjuvants covered in this patent are ca-
pable of suppressing and redirecting established Th2-polarized im-
munity. Supporting evidence for this patent application was found in 
murine models of food allergy where we discovered that therapeutic 
immunization of peanut-sensitized mice with NE and peanut led to 
protection from allergic reactivity upon exposure to peanut. Based 
on these observations, we claimed the use of NE compositions for 
the suppression of allergic disease through the suppression of Th2-
polarized immune responses.
Vaccines have made significant impacts in global health, and 
although vaccines typically aim to generate or boost immune re-
sponses, recent work has demonstrated the ability of adjuvants to 
modulate pre-existing immunity or even suppress detrimental im-
mune responses. The NE adjuvants described here were initially 
developed at the University of Michigan as broad-spectrum antimi-
crobial agents, but NEs proved to be effective mucosal adjuvants. A 
wide variety of antigen types (recombinant proteins, virus-like parti-
cles, whole virus or bacteria) have been formulated into NE droplets 
through simple mixing, resulting in association of antigen materials 
with the lipid phase of the droplets. This incorporation increases 
stability of the immunogen, as antigens are protected from denatur-
ation and degradation.5,6
MF59 and AS03 are other emulsion adjuvants currently used 
in human vaccines. These adjuvant formulations are composed of 
squalene and are neutral or negatively charged, in contrast to NE 
adjuvant which contains soybean oil and is positively charged due 
to cationic surfactants. These physiochemical differences may drive 
immune activation via distinct mechanisms of action for these emul-
sion adjuvants.
While characterizing a NE-adjuvanted hepatitis B (HepB) vac-
cine, we fortuitously discovered that in mice with pre-existing Th2 
HepB immunity from an intramuscular alum-adjuvanted HepB vac-
cine, a single i.n. immunization with NE-adjuvanted HepB induced 
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Th1-associated responses while reducing Th2 responses. The immu-
nization with NE modulated the magnitude and kinetics of the anti-
body and cellular response indicating that NE was able to redirect 
established Th2-polarized immunity towards Th1. This led to the hy-
pothesis that immunization with NE and allergens could also be used 
to suppress the aberrant Th2 immune responses associated with 
allergic hypersensitivity. This redirection of the allergen-specific 
immune response away from the harmful Th2-polarized response 
would be enhanced by induction of cellular responses associated 
with protection from allergic disease, including IFN-γ and IL-10. Our 
hypothesis is supported by studies from other investigators that 
have demonstrated that allergen immunotherapy in grass pollen al-
lergic individuals increases allergen-specific IFN-γ-producing cells, 
correlating with reduced symptoms.7 Additionally, proliferating al-
lergen-specific T cells have been found in healthy nonallergic con-
trols, suggesting that some nonallergic individuals may be protected 
from allergic manifestations due to the presence of Th1-producing 
allergen-specific cells.8 Together, this suggests that the induction 
of allergen-specific Th1-polarized immune responses along with the 
suppression of Th2 responses may induce long-term protective im-
munity against clinical allergies.
Next, we evaluated the ability of NE to modulate the Th2 and IgE 
immune responses responsible for allergic diseases in mouse models 
of food allergy. NE, when formulated with specific food allergens 
and administered intranasally three times at monthly intervals, was 
effective to suppress allergic responses on oral or systemic allergen 
challenge, providing protection from anaphylaxis in multiple murine 
models, as reflected by reduction in clinical symptoms, mast cell 
degranulation and temperature change upon challenge (Figure 2). 
This is associated with reduction of Th2 and IgE allergen-specific 
responses and activation of Th1, Th17 and regulatory T cells as 
well as IL-10-producing cells (Figures 1 and 2).9 Of interest, the NE 
significantly enhances mucosal immunity, including IgA antibodies 
that may neutralize allergen. NE-mediated suppression of Th2 aller-
gic responses and protection against anaphylaxis could be partially 
blocked by anti-IL-10, suggesting a role for IL-10-associated regula-
tory cells.
Comprehensive evaluation of acute and chronic effects of NE 
formulations has been performed to assess the safety of the intra-
nasal route of delivery of NE adjuvants. No inflammation has been 
observed in the nasal cavity in safety studies in mice, rats, guinea 
pigs and dogs.6 The association of antigen with the oil core of the NE 
droplets which are taken up by mucosal epithelial and dendritic cells 
should limit interaction between allergen and mast cells to improve 
the safety of the intranasal route of allergen immunotherapy.
Allergic disease has become a significant burden on global pub-
lic health. Until recently, most drugs used to treat allergies simply 
managed symptoms. New advances in allergen immunotherapy and 
F I G U R E  1   Modulation of allergic immunity by NE adjuvant. Allergic sensitization results in the differentiation of Th2 cells as well as 
IgE-producing B cells. Immunization with NE (A) induces Th1 and Th17 cells and (B) Tregs and IL-10-producing cells and (C) inhibits Th2 
cells. NE immunization (D) reduces production of allergen-specific IgE while (E) increasing allergen-specific IgA and IgG2a antibodies. 
Modulation of the allergic immune responses by NE results in protection from reaction upon allergen exposure through (F) decreases in 
mast cell infiltration into tissues as well as prevention of mast cell degranulation upon allergen exposure. (Inset), Structure of oil-in-water 
nanoemulsion droplet [Color figure can be viewed at wileyonlinelibrary.com]
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biological therapies have demonstrated the ability to suppress IgE 
and the allergic response. Unfortunately, to this point, only a few ap-
proaches have demonstrated the persistent modulation of the Th2-
polarized immune responses that drive allergic disease, suggesting 
an absence of immunological memory for the tolerant state. This is 
especially true for food allergies where allergic reactivity typically 
returns just weeks after cessation of therapy. In contrast to these 
studies, we have demonstrated in multiple vaccine models that 
immunization with NE adjuvant induces long-term immunological 
memory responses that could be able to more permanently redirect 
the immune system away from Th2 immunity, thereby preventing 
allergic hypersensitivity. Additionally, adjuvant-driven immune mod-
ulation could offer a less complex therapeutic regimen compared to 
current immunotherapies that require daily administration over ex-
tended periods of time. As the supporting data for this patent were 
generated in mouse models, future clinical studies will be necessary 
to determine whether these same effects occur in humans. Because 
the NE vaccine platform can be combined with virtually any antigen, 
it provides a platform to investigate any allergic disease associated 
with aberrant Th2 immune responses. It also could provide an ap-
proach to clinical investigations of suppression of allergic disease 
as the NE adjuvant has successfully completed safety studies in hu-
mans.3 The technology described here will advance the understand-
ing of mechanisms to modulate established Th2 immunity and may 
provide significant therapeutic benefit in alleviating food allergic pa-
tients and their families of the burdens of disease through long-last-
ing suppression of allergy.
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